Alexion's Soliris Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica

Alexion Pharmaceuticals, Inc. ALXN today announced that Soliris® (eculizumab), the company's first-in-class terminal complement inhibitor, has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) for the treatment of neuromyelitis optica (NMO), a life-threatening, ultra-rare neurological disorder. The positive opinion of the COMP has now been forwarded to the European Commission for final approval and publication in the community register. Soliris is not approved in any country for the treatment of patients with NMO. “We are pleased that the COMP has provided a positive opinion regarding orphan medicinal product status for Soliris for the treatment of See full press release